L. Pitrolo

发表

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

V. Positano, M. Lombardi, L. Gulino, 2013, Journal of Cardiovascular Magnetic Resonance.

Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients

P. Cianciulli, L. Cuccia, G. D'Ascola, 2012, American journal of hematology.

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.

P. Cianciulli, R. Barone, L. Cuccia, 2013, Blood cells, molecules & diseases.

Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach

V. Positano, A. Meloni, D. De Marchi, 2018, European heart journal cardiovascular Imaging.

Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study

V. Positano, A. Meloni, M. Midiri, 2015, Circulation. Cardiovascular imaging.

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection

M. Levrero, F. Bronte, A. Craxì, 2012, Haematologica.

A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation

S. Raso, L. Pitrolo, A. Maggio, 2022, Thalassemia Reports.

Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose

C. Agrati, L. De Franceschi, M. Caminati, 2022, Blood.

Italian patients with hemoglobinopathies exhibit a 5‐fold increase in age‐standardized lethality due to SARS‐CoV‐2 infection

S. Perrotta, M. Cappellini, L. De Franceschi, 2021, American journal of hematology.

Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and Function Comparison Determined by Quantitative Magnetic Resonance Imaging Early Release Paper Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and

Massimo Midiri, Massimo Lombardi, Vincenzo Positano, 2022 .

The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?

L. Cuccia, V. Caruso, A. Filosa, 2017, British journal of haematology.

Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia Intermedia Versus Thalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients

V. Positano, M. Santarelli, L. Landini, 2008, Hemoglobin.

Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial

A. Pepe, L. Cuccia, V. Caruso, 2019, British journal of haematology.

Neridronate improves bone mineral density and reduces back pain in β‐thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel‐arm, open‐label study

S. Perrotta, M. Cappellini, M. Baldini, 2012, British Journal of Haematology.

Detection of Early Cardiac Dysfunction in Patients with Beta Thalassemia by Tissue Doppler Echocardiography

N. Sanfilippo, L. Pitrolo, R. Malizia, 2011, Echocardiography.

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial

F. Bushman, M. Sadelain, J. Everett, 2022, Nature Medicine.

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial

F. Bushman, M. Sadelain, J. Everett, 2022, Nature Medicine.

Quantitative evaluation of oxidative stress status on peripheral blood in β‐thalassaemic patients by means of electron paramagnetic resonance spectroscopy

L. Valgimigli, L. Cuccia, L. Pitrolo, 2005, British journal of haematology.

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5‐year long‐term Italian multicenter randomized clinical trial

L. Pitrolo, A. Maggio, R. Di Maggio, 2015, American journal of hematology.

Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET

D. Fiorino, A. Filosa, L. Pitrolo, 2018, European journal of haematology.

Double Heterozygosity for Hb Durham-N.C. (HBB: c.344T>C) [β114(G16)Leu→Pro] and the IVS-I-110 (HBB: c.93-21G>A) Causing a Severe β-Thalassemia Phenotype

L. Pitrolo, A. Maggio, A. Giambona, 2019, Hemoglobin.

Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study

V. Positano, M. Lombardi, A. Meloni, 2011, Haematologica.

Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death.

N. Chattipakorn, A. Phrommintikul, P. Cianciulli, 2013, Blood cells, molecules & diseases.

New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia

R. Barone, L. Pitrolo, A. Maggio, 2016, Indian Journal of Hematology and Blood Transfusion.

Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major : a T 2 * MRI study

V. Positano, M. Lombardi, A. Meloni, 2011 .

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

V. Positano, M. Lombardi, A. Meloni, 2011, Haematologica.